Rob Winn, Director at VCU Massey Comprehensive Cancer Center, shared a post on LinkedIn:
“I’m excited to share that our team at VCU Massey Comprehensive Cancer Center has discovered a promising new strategy to tackle treatment-resistant T-cell lymphoma. By combining HDAC inhibitors with GGTI-2418, we can overcome cancer cell resistance and enhance tumor cell death, bringing us one step closer to more effective therapies for patients facing this aggressive blood cancer.
This work truly shows the power of collaboration and innovation here at Massey, and it’s a privilege to see science translate into hope for patients.
More posts featuring Rob Winn.